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Hussein Daoud,2 Christine Massicotte,1 Edouard Henrion,2 Ousmane Diallo,2 S2D Group,2
Masoud Shekarabi,2 Claude Marineau,2 Michael Shevell,6 Bruno Maranda,7 Grant Mitchell,1
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Little is known about the genetics of nonsyndromic intellectual disability (NSID). We hypothesized that de novo mutations (DNMs) in
synaptic genes explain an important fraction of sporadic NSID cases. In order to investigate this possibility, we sequenced 197 genes
encoding glutamate receptors and a large subset of their known interacting proteins in 95 sporadic cases of NSID. We found 11
DNMs, including ten potentially deleterious mutations (three nonsense, two splicing, one frameshift, four missense) and one neutral
mutation (silent) in eight different genes. Calculation of point-substitution DNM rates per functional and neutral site showed significant
excess of functional DNMs compared to neutral ones. De novo truncating and/or splicingmutations in SYNGAP1, STXBP1, and SHANK3
were found in six patients and are likely to be pathogenic. De novo missense mutations were found in KIF1A, GRIN1, CACNG2, and
EPB41L1. Functional studies showed that all these missense mutations affect protein function in cell culture systems, suggesting that
they may be pathogenic. Sequencing these four genes in 50 additional sporadic cases of NSID identified a second DNM in GRIN1
(c.1679_1681dup/p.Ser560dup). This mutation also affects protein function, consistent with structural predictions. None of these muta-
tions or any other DNMs were identified in these genes in 285 healthy controls. This study highlights the importance of the glutamate
receptor complexes in NSID and further supports the role of DNMs in this disorder.Introduction
Intellectual disability (ID) is defined by significant limita-
tions in adaptive behavior and intellectual function that
occurbefore18yearsofage. IDaffectsup to3%of thegeneral
population and can be broadly divided into a syndromic
form associated with morphologic and/or metabolic abnor-
malities and a nonsyndromic form characterized by the
absence of these distinguishing features. The majority of
the genes identified so far in nonsyndromic ID (NSID) are
either X-linked or autosomal recessive.1,2 Although an auto-
somal-dominant mode of inheritance is not frequently
observed inNSIDbecauseof the reduced reproductivefitness
associated with this condition, autosomal-dominant muta-
tions arising de novo may explain a large fraction of cases.
A growing body of work suggests that disruption of glu-
tamatergic synapses plays an important role in common
neurodevelopmental disorders, such as ID, autism spec-
trum disorders (MIM 209850), and schizophrenia (MIM
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mitter. Glutamate receptors can be classified into those
that form ion channel pores upon binding glutamate
(AMPA receptors [AMPARs], NMDA receptors [NMDARs],
kainate receptors [KARs]) and those that indirectly activate
ion channels through a signaling cascade that involves G
proteins (metabotropic glutamate receptors [mGluRs]).
Proteomic studies showed that NMDARs and mGluRs are
components of large protein complexes (NMDAR complex
of ~185 proteins; mGluR5 complex of ~52 proteins),
whereasAMPARs interactwith a smallernumberof proteins,
with all three groups totaling at least 221 proteins.5 These
synaptic glutamate receptor complexes (referred to herein
as GRCs) are enriched in proteins involved in synaptic plas-
ticity and learning andmemory,6–9 thus constituting attrac-
tive candidate genes for neurocognitive diseases such as ID.
The importance of the glutamatergic pathways in such
conditions is highlighted by the fact that pathogenic muta-
tions in genes encoding four glutamate receptors, GRIA3
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138253), and GRIN2B (MIM 138252), have been identified
in ID.1,10–12
We hypothesized that de novo mutations (DNMs) in
genes encoding members of the GRC could explain an
important fraction of the sporadic NSID cases. To explore
this, we sequenced 197 genes encoding glutamate recep-
tors and a large subset of their known interacting proteins
in sporadic cases of NSID. We found DNMs in 11% of the
patients. Genetic and functional observations indicate
that the majority of the identified mutations affect protein
function and may be pathogenic.Subjects and Methods
Subjects and Sample Collection
The initial cohort of sporadic NSID cases (n ¼ 95; 46 males, 49
females), most of whom were French Canadian, is described else-
where.13 In the context of this study, NSID was defined with the
following criteria: (1) diagnosis of ID established on a clinical basis
via standardized developmental or IQ tests, (2) absence of specific
dysmorphic features, as assessed by an experienced clinical genet-
icist, (3) birth weight and postnatal growth within normal limits,
(4) normal head circumference at birth, (5) absence of risk factors
such as neonatal asphyxia, prematurity, or exposure to teratogenic
drugs, (6) negative results for the following standard investiga-
tions: cytogenetic studies (karyotyping, subtelomeric fluorescence
in situ hybridization, or comparative genomic hybridization
studies) and molecular testing for the common expansion muta-
tion in FMR1 (MIM 309550), and (7) absence of dysgenetic or
specific changes on brain CT scan or MRI. The second cohort of
sporadic NSID cases (n ¼ 50; 27 males, 23 females), also mainly
of French Canadian ethnicity, was recruited according to the
same patient selection criteria. A population control group of
285 healthy French Canadians was also collected. Blood samples
were obtained from all members of these series and from each of
their parents after obtaining written informed consent and
approval from institutional ethics committees. Paternity and
maternity of each individual of all families were confirmed by
using six highly informative unlinked microsatellite markers (see
Table S1 available online for marker primer sets).
Gene Selection
We focused our attention on a list of 221 nonredundant proteins,
curated by the Genes to Cognition group, that were identified by
proteomic studies of the NR1/NR2 (NMDAR complex: 185
proteins), mGluR5 (52 proteins), and GluR2 (8 proteins).5 From
these, we selected 109 candidate genes for resequencing that (1)
code for a glutamate receptor, (2) are expressed predominantly
in the brain, (3) are required for synaptic plasticity or neurotrans-
mission, (4) influence synapse structure (synapse density,
dendritic spine, neurite extension), or (5) are required for learning
or memory. We selected 88 additional genes by searching PubMed
for other NMDAR, AMPAR, or mGluR5 interactors that met at least
one of these criteria and included all other brain-expressed gluta-
mate receptors, resulting in a total of 197 selected genes (Table S2).
Gene Screening and Bioinformatics
PCR primers targeting all coding exons and boundary intronic (at
least 50–100 bp from each side) junctions of the 197 GRC genes
were designed with Exon-Primer from the UCSC Genome Browser
(Table S3). PCR was done in 384-well plates with 5 ng of genomicThe AmeriDNA, according to standard procedures. The PCR products were
sequenced at the McGill University and Genome Quebec Innova-
tion Centre (Montre´al, Canada) on a 3730XL DNA Analyzer. In
each case, unique variants (nonrecurrent in the NSID cohort and
not in the Database of Single Nucleotide Polymorphism
[dbSNP131]) were further tested by reamplifying the fragment
from blood DNA and by resequencing the proband and both
parents with reverse and forward primers. PolyPHRED (version
5.04), PolySCAN (version 3.0), and Mutation Surveyor (version
3.10, Soft Genetics) were used for mutation detection.
Estimation of Base Pairs Screened
The total number of sequenced bases was estimated for each gene
based on genomic coordinates of each amplicons successfully
sequenced; we excluded the primer sequences from these esti-
mates because the first ~20 bases from a sequencing read are
usually either undetectable or of low quality. Overlapping ampli-
cons were merged to form a single genomic interval, and coding
and noncoding sequences for each gene were annotated according
to the refFlat table from the UCSC Genome Browser. Nonsynony-
mous and synonymous sites were estimated at 71.2% and 28.8%
of the coding sites, respectively, whereas the number of CpG sites
was estimated at 2.8% of coding and at 1% of intronic sites, as
previously described.14
Expression Constructs
Mutations inKIF1A (MIM601255),GRIN1 (MIM138249),CACNG2
(MIM 602911), and EPB4L1 (MIM602879) were introduced by site-
directedmutagenesis into their corresponding positions in the pub-
lished rat cDNA expression constructs encoding KIF1A motor
domain (MD, aa 1–365)-EGFP,15 NR1A,16 NR2B,16 myc-tagged star-
gazin,17 and 4.1N,18,19 respectively. For 4.1N, the human Pro854
position corresponds to Pro852 in the rat, which was mutated to
serineherein by site-directedmutagenesis; for the sake of simplicity,
we refer to it in Figure 3 as 4.1N-P854S.
Expression in Oocytes and Voltage-Clamp Recording
Xenopus laevis oocytes were coinjected with rat NR2B and either
wild-type NR1 or NR1-E662K or NR1-S560dup complementary
RNAs, and macroscopic currents were measured as previously
described.16
Cell Culture, Transfection, Coimmunoprecipitation,
Immunoblotting, and Immunofluorescence
These standard techniques were done as previously described for
KIF1A20 and EPB41L/4.1N.18,19
Structure Prediction of the NR1 Subunit
To build three-dimensional (3D) protein structuremodels, we used
SWISS-MODEL Workspace, a Web-based integrated service dedi-
cated to protein structure homology modeling.21,22 The AMPA-
sensitive rat GluA2 receptor (Protein Data Bank ID: 3KG2) and
the rat NR1A subunit were selected as the template and the target
sequence.23 The target sequence was submitted to both ‘‘Auto-
mated Mode’’ and ‘‘Alignment Mode.’’ The structures were visual-
ized with PyMOL viewer version 0.99.
Recording of Miniature Excitatory
Postsynaptic Current
Whole-cell recordings were made from cortical cultures. Small fire-
polished patch electrodes (7–9 MU) were used. The series resis-
tance in these recordings varied between 30 and 35 MU, and
data sets in which series resistance varied more than 10% duringcan Journal of Human Genetics 88, 306–316, March 11, 2011 307
Table 1. Summary of Identified Variants
Variant
Class
Nonrecurrent Recurrent
TotalTotal dbSNP Unique DNM Total dbSNP
Not in
dbSNP
Nonsense 4 0 4 3 0 0 0 4
Missense 285 64 221 4 167 132 35 452
Silent 309 110 199 1 373 350 23 682
In-frame
INDELS
5 0 5 0 8 4 4 13
Frameshift
INDELS
2 0 2 1 0 0 0 2the recording were rejected for further analysis. No electronic
compensation for series resistance was employed. The patch elec-
trode solution contained the following: 115 mM CsMeSO4,
0.4 mM EGTA, 5 mM TEA-Cl, 2.8 mM NaCl, 20 mM HEPES,
3 mM Mg-ATP, 0.5 mM Na-GTP, 10 mM Na-Phosphocreatine (pH
7.2), and osmolarity between 290 and 292mosmol1. The extracel-
lular solution was of the following composition: 143 mM NaCl,
5 mM KCl, 10 mM HEPES, 10 mM glucose, 2 mM CaCl2,
0.0005 mM TTX, 0.1 mM Picrotoxin (pH 7.4), and osmolarity
between 302 and 305 mosmol1. During the basal recording of
miniature excitatory postsynaptic current (mEPSC), cells were
voltage clamped at 65 mV. Electrophysiological data were
acquired via a multiclamp 700B amplifier (Axon Instruments),
and signals were digitized at 10 kHz and low pass filtered at 2 kHz.Splice 4 0 4 2 0 0 0 4
Intronic 321 110 211 0 822 708 114 1143
Data from sequencing 197 glutamate receptor complex genes in 95NSID cases.
Nonrecurrent variants are those seen only once in the NSID cohort. Unique
variants are those that are nonrecurrent and also not found in dbSNP131. Splice
denotes variants in the canonical consensus splice sites (GT/AG). Intronic
variants presented herein do not include canonical splice variants.Results
Sequence Variants Identified in the NSID Patients
We sequenced the coding exons and their intronic bound-
aries of 197 GRC genes (193 autosomal, four X-linked) in
95 patients with sporadic NSID (see Subjects and Methods
for gene selection and Table S2 for gene list). We chose
sporadic cases to increase the likelihood of finding patho-
genic DNMs. On average, 95% of all amplicons were
successfully sequenced, representing ~91 Mb of coding
and ~85Mb of flanking intronic diploid sequence. In total,
we identified 2300 variants (1153 coding and 1147 in-
tronic) (Table 1; see Table S4 for list of all variants). Of
these, 646 variants were found only once in the NSID
cohort and were not previously reported in the dbSNP131,
including 225 nonsynonymous (four nonsense and 221
missense), 199 synonymous, seven insertions/deletions
(INDELs; two out-of-frame INDELs, five in-frame INDELs),
and four variants affecting the consensus canonical splice
sites. Because these unique variants are more likely to be de
novo, we further studied them by determining whether
they were transmitted from one of the parents. In this set
of 646 variants, we identified 11 DNMs, including three
nonsense, one 1 bp deletion frameshift, two splicing,
four missense, and one synonymous variant, all found in
different patients (Table 2). The other unique variants
were found to be transmitted from healthy parents and,
therefore, are unlikely to be disease causing on their
own. Clinical profiles of the patients with DNMs are out-
lined in Table 3.De Novo Truncating and Splicing Mutations
We identified three truncating DNMs in SYNGAP1 (MIM
603384; c.412A>T/p.Lys138X; c.1735C>T/p.Arg579X;
c.2438delT/p.Leu813ArgfsX23), as well as one truncating
(c.1162C>T/p.Arg388X) and one splicing (c.169þ1G>A)
DNM in STXBP1 (MIM 602926; Table 2). We recently re-
ported the identification of these DNMs in SYNGAP1 and
STXBP1 in patients with moderate-to-severe ID, and we
reported the absence of DNMs or deleterious mutations in
these two genes in 190 controls.13,24 Another DNM,
affecting the splice acceptor site in intron 5 (c.601-1G>A)308 The American Journal of Human Genetics 88, 306–316, March 1of SHANK3 (MIM 606230), was found in a male with mild
ID and severe language impairment (Table 3). RT-PCR
showed that this mutation interferes with the splicing of
exon6, resulting ina frameshift at position211 and aprema-
ture stop codon (Figure S1). No truncating or splicingmuta-
tions were identified in SHANK3 in 475 control individuals
that we previously sequenced and reported elsewhere.25,26
Missense and Silent DNMs
De novo missense mutations were identified in KIF1A
(c.296C>T/p.Thr99Met),GRIN1 (c.1984G>A/p.Glu662Lys),
EPB41L1 (c.2560C>T/p.Pro854Ser), andCACNG2 (c.427G>
C/p.Val143Leu) (Table 2). These mutations affect evolution-
arily conserved amino acid residues (Figure S2) and are pre-
dicted to affect protein function by widely used prediction
algorithms (SIFT,27 PloyPhen,28 or Panther29). In addition,
a de novo synonymous mutation (c.735A>G/p.Thr245Thr)
was identified in DRD1 (MIM 126449), which encodes
for the dopamine receptor D1. This variant is unlikely to
have any functional consequence, because it does not
change the amino acid sequence and is not predicted to
affect mRNA splicing. Sequencing these four genes in 50
additional patients with sporadic NSID identified a de novo
in-frame 3 bp duplication in GRIN1 (c.1679_1682dup/
p.Ser560dup) (Table 2 and Table S4). These four genes were
subsequently sequenced in285controls, andneitherof these
DNMs, nor any de novo or evidently deleterious mutations
(such as truncating or splicing mutations), were identified
(Table S5).
Functional Impact of p.Thr99Met on KIF1A
TheKIF1Ap.Thr99MetDNMwas identified ina femalewith
moderate ID (Table 3). KIF1A encodes a kinesin motor
protein that transports synaptic vesicle precursors from
the cell body to the tips of axons. KIF1A is composed of
an N-terminal motor domain, followed by regulatory and1, 2011
Table 2. DNMs Identified in NSID Patients
DNM Gene Chromosome RefSeq Number Protein (aa) Predicted DNM Effect
Truncating/Splicing
c.412A>T; p.Lys138X SYNGAP1 6 NM_006772.2 1343 truncating
c.1735C>T; p.Arg579X SYNGAP1 6 NM_006772.2 1343 truncating
c.2438delT; p.Leu813ArgfsX23 SYNGAP1 6 NM_006772.2 1343 truncating
c.1162C>T; p.Arg388X STXBP1 9 NM_003165.3 603 truncating
c.169þ1G>A (splicing) STXBP1 9 NM_003165.3 603 truncating (RT-PCR-fs)
c.601-1G>A (splicing) SHANK3 22 NM_01080420.1 1747 truncating (RT-PCR-fs)
Missense
c.296C>T; p.Thr99Met KIF1A 2 NM_004321.4 1690 damaging (SIFT, PolyPhen, Panther)
c.427G>C; p.Val143Leu CACNG2 22 NM_006078.3 323 damaging (SIFT, PolyPhen, Panther)
c.2560C>T; p.Pro854Ser EPB41L1 20 NM_012156.2 881 damaging (SIFT, PolyPhen, Panther)
c.1984G>A; p.Glu662Lys GRIN1 9 NM_007327.3 938 damaging (Panther)
In-Frame Duplication1
c.1679_1681dup; p.Ser560dup GRIN1 9 NM_007327.3 938 NA
Synonymous
c.735A>G; p.Thr245Thr DRD1 5 NM_000794.3 446 neutral
RT-PCR-fs denotes transcripts detected by RT-PCR and found, by sequencing, to result in frameshifts. Damaging denotes according to predictions by SIFT,
PolyPhen, or Panther. NA denotes not applicable.
1 Not identified in the primary screen (NSID, n ¼ 95) but found in the targeted secondary screen of a second cohort of NSID patients (n ¼ 50).cargo-binding domains.30,31 Thr99 lies in the highly
conserved p loop consensus ATP-binding site of the KIF1A
motor domain (GQT99XXGKT/S) (Figure S2). To determine
whether p.Thr99Met affects KIF1A movement along neu-
rites, we transfected primary rat hippocampal neuronsTable 3. Clinical Phenotype of the Patients with Functional DNMs
Patient Gene DNM Age Sex ID
Patient 1 SYNGAP1 p.Lys138X 4 yr 5 mo F þþ/þþ
Patient 2 SYNGAP1 p.Arg579X 5 yr 10 mo F þþ/þþ
Patient 3 SYNGAP1 p.Leu813ArgfsX23 12 yr 10 mo F þþ/þþ
Patient 4 STXBP1 p.Arg388X 15 yr F þþþ
Patient 5 STXBP1 c.169-1G>A 27 yr F þþþ
Patient 61 SHANK3 c.601-1G>A 15 yr M þ
Patient 7 KIF1A p.Thr99Met 3 yr 5 mo F þþþ
Patient 8 GRIN1 p.Glu662Lys 10 yr F þþ
Patient 9 GRIN1 p.Ser560dup 7 yr 6 mo M þþþ
Patient 10 EPB41L1 p.Pro854Ser 6 yr M þþþ
Patient 11 CACNG2 p.Val143Leu 8 yr M þþ
Detailed clinical profiles of the patients (1–5) with DNMs in SYNGAP1 and STXBP1w
þþþ denotes severe. The following abbreviations are used: ND, not determined
1 Assessment with the Autism Diagnostic Observation Schedule-Generic at 15 ye
2 Mild atrophy of the vermian region of the cerebellum on the MRI (Figure S5).
The AmeriwithdifferentKIF1AMD-EGFP fusion constructs, including
wild-type (KIF1A-MD) or mutant motor domains contain-
ing either p.Thr99Met (KIF1A-MD-T99M) or p.Thr312Met
(KIF1A-MD-T312M) mutation, which was previously
shown to affect the motor activity of KIF1A.15 KIF1A-MDEpilepsy Neurological Examination MRI CT Scan
þ GEN normal normal ND
þ GEN normal normal ND
þ  normal ND normal
PC hypotonia normal normal
PC hypotonia ND normal
 normal ND normal
 axial hypotonia/peripheral
spasticity
atrophy2 ND
 normal ND normal
PC hypotonia normal ND
 hypotonia normal ND
 normal normal ND
ere described elsewhere.13,24 ID scale:þ denotes mild,þþ denotes moderate,
; GEN, generalized epilepsy; PC, partial complex epilepsy.
ars of age was not suggestive of autism.
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Figure1. Impactofp.Thr99MetonKIF1ASubcellular Localization
EGFP-tagged motor domain (MD) constructs of KIF1A were ex-
pressed in cultured hippocampal neurons and visualized by immu-
nofluorescence staining with an anti-EGFP. The MD of wild-type
(WT) KIF1A (KIF1A-MD) accumulated in the axons (arrow heads),
in contrast to KIF1A-MD-T99Mor KIF1A-MD-T312M. The neuronal
cell bodies and dendrites were stained with anti-MAP2 antibody.
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Figure 2. Impact of GRIN1 p.Glu662Lys and p.Ser560dup on
NMDAR Function
Xenopus oocytes were coinjected with mRNAs of NR2B and either
wild-type NR1 or mutated NR1 (E662K or S560dup).
(A) Current-voltage curves of Naþ and Ba2þ currents. I-V curves for
GluþGly-activated currents were measured by voltage ramps withaccumulated in distal regions of neurites, whereas both
KIF1A-MD-T312M and KIF1A-MD-T99M showed greatly
reduced distal localization and increased accumulation
throughout the cell body and proximal neurites (Figure 1).
Na saline and Ba saline.
(B) Inward current induced by 10 mMglycine and 10 mMglutamate
(Vh ¼ 70 mV) in oocytes coinjected with NR2B and either
wild-type NR1 or NR1-S560dup mRNAs. Inset: enlargement of
the mutant NR1 signal. Values are means 5 standard error of
the mean (SEM) of eight independent experiments.
(C) Conformational change of NR1 caused by p.Ser560dup. Top:
amino acid sequences flanking the M1 transmembrane region
are shown. The position of p.Ser560dup, resulting in the addition
of a Ser561, is shown and indicated by an arrow head. Bottom:
a 3D representation of the rat NR1 receptor subunit (WT and
NR1-S560dup).M1,M2, andM3 represent transmembrane regions
constituting the channel pore. The entrance to the channel pore
(boxed) is significantly altered by the p.Ser560dup mutation.Functional Impact of p.Glu662Lys and p.Ser560dup
on GRIN1
The p.Glu662Lys mutation was identified in a female with
mild-to-moderate ID, whereas the p.Ser560dup mutation
was found in a male with severe ID and epilepsy (Table 3).
GRIN1 encodes the essential NMDAR subunit NR1, which
associates with other subunits to form a heteromeric
ligand-gated Ca2þ ion channel. The p.Glu662Lys DNM lies
in the posttransmembrane (TM) region 3 of NR1, whereas
p.Ser560dup is located just before TM1 (Figure S2). To test
the effect of both mutations on NMDAR activity, we coin-
jected Xenopus oocytes with NR1/NR2B, NR1-E662K/
NR2B, or NR1-S560dup/NR2B mRNAs and performed elec-
trophysiology. To minimize Ca2þ-activated Cl currents,
which could be toxic to the cells, we compared Ba2þ
currents instead of Ca2þ currents with Naþ currents in
both NR1/NR2B and NR1-E662K/NR2B via voltage clamp.
Ba2þ currents were greater than Naþ currents in NR1-
E662K/NR2B transfected cells, but both Ba2þ and Naþ
currents were nearly equal in NR1/NR2B transfected cells
(Figure 2A). The affinity of the receptor to the agonist
glycine and its response to Mg2þ block were not affected
by p.Glu662Lys (Figure S3). Interestingly, the effect of
p.Ser560dup was more pronounced, almost abolishing310 The American Journal of Human Genetics 88, 306–316, March 1the activity of the receptor (Figure 2B). To test the effect
of this insertion on the structure of the receptor, we built
a three-dimensional model of the rat NR1A by using the
available X-ray structure of the closely related rat GluA2
AMPAR23 as a template and showed that the p.Ser560dup
is predicted to significantly alter the 3D structure at the
receptor’s channel pore entrance (Figure 2C).
Impact of p.Pro854Ser on EPB41L1 Binding to AMPAR
The p.Pro854Ser in EPB41L1 was found in a male with
severe ID (Table 3). EPB41L1 encodes a neuronal cytoskel-
etal protein known as 4.1N, which binds to AMPAR
subunits through its C-terminal domain and regulates1, 2011
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Figure 3. Functional Impact of the
p.Pro854Ser EPB41L1 Mutation
(A) Indicated plasmid combinations (wild-
type 4.1N [WT], 4.1N-P854S [P854S], myc-
GluR) were cotransfected in HEK293 cells,
and extracted proteins were immunopre-
cipitated with an anti-myc antibody and
then analyzed by immunoblotting with
anti-myc or anti-4.1N antibodies. The
amount of coIP of 4.1N was reduced in
the cells transfected with the 4.1N-P854S
mutant. Right: the quantification of coIP
experiment (mean5 SEM,n¼ 3, *p< 0.05,
t test).
(B) Hippocampal neurons were cotrans-
fected with GFP-GluR1 and the indicated
4.1N constructs. Surface GluR1was stained
by anti-GFP antibody in nonpermeabilized
conditions and visualized by staining with
a secondary anti-rabbit IgG (Alexa 568).
Right: the quantification of GluR1 surface
expression in presence of mutant or wild-
type 4.1N (signal with WT adjusted to 1;
mean5 SEM, n ¼ 4, two-tailed Student’s t
test, *p < 0.05)their expression at the synaptic membrane.18,19 Because
p.Pro854Ser affects a highly conserved residue in this
C-terminal domain, we tested whether it disrupts the
interaction of 4.1N with the AMPAR subunit GluR1 in
transfected HEK293 cells. Coimmunoprecipitation (coIP)
studies showed that p.Pro854Ser reduces the binding of
4.1N to GluR1 by 50% in these cells (Figure 3A). Moreover,
insertion of the AMPAR subunit GluR1 at the synaptic
membrane was significantly decreased in transfected
hippocampal neurons producing mutant 4.1N when com-
pared to cells producing wild-type 4.1N (Figure 3B).
Impact of p.Val143Leu on CACNG2 Binding
to AMPAR
The DNM p.Val143Leu was identified in a male with
moderate ID (Table 3). CACNG2 encodes stargazin (also
known as TARP-g2), a synaptic adaptor protein that binds
to AMPAR and regulates its synaptic trafficking, as well
as its channel properties.32,33 We investigated whether
p.Val143Leu, which lies in the TM3 of stargazin, affects
its interaction with AMPARs in transfected HEK293 cells.
CoIP studies showed that p.Val143Leu significantly
decreases stargazin’s ability to bind to GluR1 or GluR2
AMPAR subunits in these cells (Figure 4A). In addition,
cell surface expression of GluR1 was reduced in transfectedThe American Journal of Human Ghippocampal neurons (Figure 4B) and
HEK293 cells (Figure S4) producing
mutant stargazin, as compared to
cells producing the wild-type protein.
Consistent with these findings,
expression of stargazin-V143Lmutant
decreased both miniEPSC amplitude
and frequency in transfected hippo-
campal neurons, suggesting thatp.Val143Leu caused a reduction in glutamatergic transmis-
sion (Figure 4C).
Excess of Functional De Novo Mutations in NSID
Wenext sought to determinewhether the identified nonsy-
nonymous or splicing (referred to herein as functional)
point substitution DNMs (p.DNMs) were found in excess
compared to neutral ones (nonsplicing intronic, synony-
mous) in our NSID cohort, which would suggest that
a subset of these DNMs are pathogenic. We sequenced
~107 Mb (diploid) of neutral sites and identified only one
synonymous p.DNM, resulting in a neutral p.DNM rate of
0.93 3 108 mutations per bp per generation. This result
is consistent with direct DNM rate estimates (~1.0 3 108)
derived from recent family-based whole-genome sequenc-
ing control studies.34,35 Basedonour estimate of theneutral
p.DNMrate,wewould expect ~0.6 p.DNMs in the ~66.7Mb
of sequenced functional sites (nonsynonymous and
splicing). Instead, we identified nine functional p.DNMs,
representing a significant enrichment in functional versus
neutral DNMs in the NSID cohort (p ¼ 0.001). This excess
remained significant even when we accounted for the fact
that CpG dinucleotides mutate at a faster rate than other
sites and are more common in exons than introns (p ¼
0.002; Table 4). Finally, we found that the proportion ofenetics 88, 306–316, March 11, 2011 311
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Figure 4. Functional Impact of the
p.Val143Leu CACNG2 Mutation
(A) Indicated combinations of expression
plasmids (wild-type myc-tagged stargazin
[myc-Stg], myc-tagged stargazin-V143L
[V143L], GFP-GluR1, GFP-GluR2) were co-
transfected in HEK293 cells, and extracted
proteins were immunoprecipitated with an
anti-myc antibody and then analyzed by
immunoblotting with anti-myc or anti-
GFP antibodies. The amount of coIP of
AMPARs (both GluR1 and GluR2) with Stg
was reduced in the Stg-V143L transfected
cells. Right: the quantification of the
coIP experiments (mean 5 SEM, n ¼ 3,
*p< 0.05, t test).
(B) Hippocampal neurons were transfected
with GFP-GluR1 and indicated Stg
constructs at DIV19 and stained with an
anti-GFP (to detect surface GluR1) in
nonpermeabilized conditions at DIV20.
Stg-V143L results in reduced surface and
total GluR1. Right: quantification of stain-
ing results (mean 5 SEM, n ¼ 4, **p <
0.01, *p< 0.05, t test).
(C) Hippocampal neurons were cotrans-
fected with the indicated Stg constructs
and GFP at DIV19, and miniature EPSCs
were recorded at DIV22/23 from GFP-
expressing neurons. Recordings were done
in voltage-clamp mode at 65 mV in the
presence of an extracellular solution con-
taining 0.5 mM tetrodotoxin (TTX)/100 mM
picrotoxin to detect excitatory mEPSC
events. Expression of Stg-V143L mutant
decreases both mEPSC amplitude and
frequency. Right: results quantification
(mean 5 SEM, n ¼ 4, *p < 0.05, t test,
***p < 0.001, t test).functional p.DNMs to neutral ones was increased when
compared to all segregating or unique variants (p < 0.001;
Table 5). We did not include INDEL DNMs in all these
comparisons because no neutral INDELs (e.g., affecting
nonsplicing intronic sites) were identified.Discussion
Pathogenicity of the De Novo Truncating Mutations
The truncating DNMs identified in SYNGAP1 and STXBP1
are likely pathogenic based on the observations that (1)
truncating mutations were not found in these genes in
a large series of controls, (2) truncations of the correspond-
ing proteins abolish important functional domains, and
(3) haploinsufficiency of these genes affects cognitive
processes and/or neurotransmission in mice.13,24
The splicing DNM identified in SHANK3 is also likely path-
ogenic based on its functional impact and the documented
involvement of SHANK3 in related neurodevelopmental312 The American Journal of Human Genetics 88, 306–316, March 1diseases. SHANK3 is a PDZ-containing scaffold protein
that is localized in the postsynaptic density, where it asso-
ciates with glutamate receptors and promotes formation of
functional synapses.36–38 The splicing DNM identified
here in SHANK3 is predicted to cause a frameshift upstream
of the PDZ domain and Homer and cortactin binding
sites (Figure S1), a region where pathogenic SHANK3
DNMs were previously reported in autism and schizo-
phrenia.25,26,39
Pathogenicity of the De Novo Missense
and In-Frame Duplication Mutations
Missense DNMs were identified in KIF1A,GRIN1, EPB41L1,
and CACNG2 in the course of the initial NSID cohort
screen. Subsequently, sequencing these genes in 50 addi-
tional NSID patients identified a second DNM in GRIN1,
resulting in an in-frame duplication of an amino acid.
These DNMs involve well-conserved residues, are predicted
to be damaging, and affect protein function in cell culture
systems. Although sequencing these genes in larger1, 2011
Table 4. Base Pairs Sequenced and Point Substitution DNMs
Identified
Initial Count CpG Non-CpG Effective Count
Functional
NS 64,601,865 1,808,852 62,793,013 80,881,535
Splice 2,144,740 21,447 2,123,293 2,337,767
Total 66,746,605 1,830,300 64,916,306 83,219,302
p.DNMs 9 4 5 9
Neutral
Syn 26,131,092 731,671 25,399,421 32,716,127
Intronic 80,932,933 809,329 80,123,604 88,216,897
Total 107,064,025 1,541,000 105,523,025 120,933,024
p.DNMs 1 0 1 1
p value 0.001 0.002
The following abbreviations are used: NS, nonsynonymous (missense,
nonsense); syn, synonymous; p.DNMs, point substitution DNMs. Nonsynony-
mous and synonymous sites were estimated at 71.2% and 28.8% of coding
sites, respectively. Effective count accounts for increased CpG mutation
rate ¼ CpG 3 10 þ non-CpG sites, where CpG sites were estimated to consti-
tute 2.8% of initial coding sites and 1% of intronic sites.14 p value, Fisher’s
exact test.
Table 5. Comparison of p.DNMs to Segregating Variants
Functional Neutral
Functional/
Neutral p Value
p.DNMs 9 1 9
Unique variants 229 410 0.56 <0.001
All variants 460 1825 0.25 <0.001
Functional denotes nonsynonymus þ splice variants. Neutral denotes synony-
mus þ nonsplice intronic sites variants. p value, Fisher’s exact test.cohorts is needed to further ascertain their involvement in
NSID, genetic and functional evidence argue in favor of
this possibility. Homozygous deletion of Kif1a in mice
results in insufficient neuronal contact and impaired
neurotransmission, leading to perinatal death.40 Several
de novo deletions encompassing KIF1A and other genes
have been reported in patients with ID and autism, further
suggesting that heterozygous KIF1A disruption may be
involved in NSID.41 Our functional studies indicate that
p.Thr99Met impairs the ability of KIF1A to localize to distal
aspects of neurites, consistent with the fact that the Thr99
residue lies in the conserved ATP-binding p loop of the
motor domain of KIF1A. Interestingly, the heterozygous
p.Gln98Leu mutation in KIF1Bb (MIM 605995), which
was reported in a family with autosomal-dominant
peripheral neuropathy, affects a residue immediately adja-
cent to Thr99 in the conserved ATP-binding domain
(GQ98T99XXGKT/S).42 Although KIF1A and KIF1Bb share
a similar primary structure, their expression patterns and
the composition of their cargo are somewhat different,
possibly explaining the distinct phenotypes associated
with these genes.30 Nonetheless, even though nerve
conduction velocities were normal in our patient, the
development of a neuropathy at a later age cannot be ruled
out. KIF1A can homodimerize, raising the possibility that
deleterious heterozygous mutations at critical sites may
act as dominant negatives.43 Additional work is needed
to investigate whether this is the case for p.Thr99Met.
GRIN1 encodes NR1, an essential subunit of the NMDAR
that plays a critical role in synaptic plasticity and learning
and memory. Homozygous NR1 deletions are embryonic
lethal, whereas reduced NR1 expression in mice results inThe Ameribehavioral abnormalities and impaired synaptic plasticity
andmemory.44–46Moreover, denovodeleteriousmutations
in GRIN2A and GRIN2B, which encode the two main
subunits that associate with GRIN1 to form functional
NMDARs, were recently reported in patients with ID.10
The p.Glu662Lys mutation caused a significant increase
in NMDAR-induced Ca2þ currents. Excessive Ca2þ influx
through NMDAR could lead to excitatoxic neuronal cell
damage,47,48 which may, in turn, be responsible for cogni-
tive deficits. On the other hand, the p.Ser560dup almost
abolished the activity of the receptor. Thismaybe explained
by the significant structural change that this insertion is
predicted to cause at the entrance of the channel pore.
Collectively, these observations suggest that the GRIN1
DNMs identified herein may be pathogenic.
The two other missense DNMs reported herein were
found in CACNG2 and EPB41L1, which encode AMPAR
adaptorproteins that regulate the trafficking and/or activity
of the receptor.18,19,32,33 Transfection studies in HEK293
cells and hippocampal neurons showed that both DNMs
caused a significant reduction in the ability of stargazin
and 4.1N to bind to AMPAR, resulting in a decrease in the
surface expression of GluR1/2 subunits. Abnormal AMPAR
trafficking and/or activity has been linked to ID, as outlined
below, suggesting a possible mechanism for the potential
pathogenicity of these DNMs.
Disruption of AMPAR Signaling and/or Trafficking
in NSID
The majority of the DNMs reported herein affect genes
that are involved directly or indirectly in AMPAR traf-
ficking. Indeed, EPB41L1, CACNG2, and SYNGAP1 have
all been shown to regulate AMPAR trafficking.19,33,49
Furthermore, emerging evidence also suggests that
KIF1A, SHANK3, and GRIN1 may also play a role in regu-
lating AMPAR trafficking. KIF1A interacts with AMPARs
via its liprin-alpha domain, and therefore could potentially
act as a neuronal AMPAR transporter.31 SHANK3 has been
reported to directly interact with GluR1 and to influence
the recruitment of functional AMPARs to dendritic
spines.37,38 As for GRIN1, a recent report showed that
phosphorylation of NR1 at certain residues reduces
synaptic AMPAR levels in vivo.50 Moreover, NMDAR
activity can influence pathways involved in the regulation
of AMPAR trafficking. Regulation of AMPAR trafficking is
critical for synaptic plasticity and learning and memory,can Journal of Human Genetics 88, 306–316, March 11, 2011 313
and dysfunction of this process has the potential of
causing cognitive disorders.51 For instance, mutations in
GRIA3, which encodes for an AMPAR subunit, and in
several genes known to affect AMPAR trafficking (such as
PAK3 [MIM 300142], OPHN1 [MIM 300127], FMR1, and
DLG3 [MIM 300189]) have been previously shown to cause
forms of ID.1,12,52–55
Contribution of DNMs in Synaptic Genes to NSID
By focusing our resequencing effort on candidate GRC
genes, we identified DNMs in ~11% of the NSID cases.
The fact that 10 out of the 11 DNMs were functional and
likely pathogenic supports the role of DNMs in NSID and
highlights the importance of the glutamatergic pathways
in this disease. This is in agreement with a recent exome
sequencing of ten individuals with ID and identification
of nine DNMs, two of which were truncations in known
ID synaptic genes, RAB39B (MIM 300774) and SYNGAP1.56
Finally, recent sequencing of candidate synaptic genes in
autism spectrum disorders and schizophrenia also reported
an excess of functional DNMs in these diseases.14 This
observation further supports the notion that ID, autism
spectrum disorders, and schizophrenia may share
a common synaptic component.Supplemental Data
Supplemental Data include five figures and five tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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